Regeneron Pharmaceuticals, Inc.

(NASDAQ Global Select)
Back to all articles
Bearish -65

Regeneron drops after skin cancer treatment misses late-stage trial goal

AI-generated analysis

πŸ“‰ REGN shares fell 12% after the fianlimab and cemiplimab combination failed to reach statistical significance in a late-stage trial for advanced melanoma.

πŸ’Š The experimental treatment showed a median progression-free survival of about five months longer than Merck's Keytruda, but the difference was not statistically significant.

πŸ“‰ This is the second consecutive pipeline miss for Regeneron, following delays for Eylea and the failure of itepekimab last year.

πŸ’° Shares dropped to $612.06, putting the company on track to lose approximately $9 billion in market value.

πŸ“‰ At least 10 brokerages cut their price targets on Regeneron following the announcement.

πŸ”¬ Regeneron is now conducting a separate head-to-head trial comparing its fianlimab combination with Bristol Myers Squibb's Opdualag.

🀝 Separately, Regeneron partnered with Parabilis Medicines to develop treatments for hard-to-reach disease targets.

πŸ’΅ The partnership could result in up to $2.2 billion in milestone payments for Parabilis.

Bullish Signals
  • The experimental combination therapy demonstrated a median progression-free survival of about five months longer than Merck's Keytruda, indicating potential clinical efficacy despite the lack of statistical significance.
  • Regeneron has secured a new strategic partnership with privately held Parabilis Medicines to develop treatments for hard-to-reach disease targets.
  • The partnership agreement includes potential milestone payments totaling up to $2.2 billion, providing significant future revenue visibility.
Risk Factors
  • The late-stage trial failed to reach statistical significance in improving progression-free survival for patients with advanced melanoma.
  • Analysts described the results as a worst-case scenario, noting that sentiment is likely to worsen even if the immediate business impact is limited.
  • Regeneron is facing back-to-back key pipeline misses, which are expected to increase pressure on its clinical development schedule over the next 12 to 18 months.
  • At least 10 brokerages have cut their price targets on Regeneron's stock following the trial results.
  • Shares fell 12% in morning trade, putting the company on track to lose about $9 billion in market value.
Full Analysis
Regeneron Pharmaceuticals (REGN) shares dropped approximately 12% in morning trade on Monday, May 18, following the announcement that a late-stage clinical trial for its experimental skin cancer treatment failed to meet its primary endpoint. The combination therapy of fianlimab and cemiplimab did not achieve statistical significance in improving progression-free survival for patients with advanced melanoma compared to Merck's Keytruda. This setback marks the second consecutive major pipeline failure for the company, following regulatory delays for a pre-filled syringe version of its eye drug Eylea and the late-stage failure of its lung disease drug itepekimab last year. Analysts from BMO Capital Markets and Evercore describe the situation as high pressure on Regeneron's clinical development roadmap over the next 12 to 18 months, with at least 10 brokerages cutting their price targets. Despite the trial miss showing a median progression-free survival of about five months longer than the comparator, the lack of statistical significance led analysts to label the results as a worst-case scenario. The company is now conducting a separate head-to-head trial against Bristol Myers Squibb's Opdualag, though some investors express low confidence in that outcome. Separately, Regeneron announced a partnership with Parabilis Medicines involving potential milestone payments up to $2.2 billion for new treatments.